Stockscreener 앱 받기
29.97
0.43%
-0.13
시간 외 거래:
29.97
전일 마감가:
$30.10
열려 있는:
$30.13
하루 거래량:
358.53K
Relative Volume:
0.56
시가총액:
$1.72B
수익:
$32.87M
순이익/손실:
$674.31M
주가수익비율:
2.6382
EPS:
11.36
순현금흐름:
$-330.11M
1주 성능:
+1.18%
1개월 성능:
+16.34%
6개월 성능:
-35.82%
1년 성능:
-13.23%
1일 변동 폭
$29.80
$30.50
1주일 범위
$27.19
$31.55
52주 변동 폭
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
29.97 | 1.72B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 | AGIO Stock News - GuruFocus
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Nasdaq
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 - The Manila Times
Agios Pharmaceuticals Inc Reports Q1 2025 EPS of -$1.55, Beating - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlight - GuruFocus
Agios Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AGIO) - Seeking Alpha
Agios (AGIO) Reports Lower Q1 Revenue as sNDA for Thalassemia Pr - GuruFocus
Agios Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Agios Pharmaceuticals Shares Down After Q1 Net Loss Widens, Revenue Misses Estimates - marketscreener.com
AGIOS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Earnings call transcript: Agios Pharm beats EPS expectations in Q1 2025 - Investing.com
Agios Q1 2025 slides: PYRUKYND sales dip QoQ, pipeline advances toward key catalysts - Investing.com
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Agios Pharmaceuticals: Q1 Earnings Snapshot - MySA
Agios Reports First Quarter 2025 Financial Results and Recent Bu - GuruFocus
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q1 Loss of $-1.55, vs. FactSet Est of $-1.81 Loss - marketscreener.com
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - ADVFN
An Overview of Agios Pharmaceuticals's Earnings - Nasdaq
Long Term Trading Analysis for (AGIO) - news.stocktradersdaily.com
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for - MSN
BofA Adjusts Price Target on Agios Pharmaceuticals to $52 From $54, Keeps Buy Rating - marketscreener.com
Agios Pharmaceuticals (AGIO) Price Target Lowered by BofA but Buy Rating Maintained | AGIO Stock News - GuruFocus
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 | AGIO Stock News - GuruFocus
Agios Pharmaceuticals to Host Conference Call for Q1 2025 Financial Results on May 1, 2025 - Nasdaq
Rare Disease Biotech Agios Sets Q1 2025 Earnings Call: Key Updates Expected May 1 - Stock Titan
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 - The Manila Times
Anemia Market Set to Witness Significant Growth by 2032, Driven by Rising Awareness and Novel Oral Alternatives | DelveInsight - Barchart.com
Trexquant Investment LP Increases Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock By Investing.com - Investing.com India
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock - Investing.com Australia
Agios Pharmaceuticals Director Sells Shares to Cover Tax Obligations - TradingView
Agios stock touches 52-week low at $24.33 amid market challenges - Investing.com Australia
Agios stock touches 52-week low at $24.33 amid market challenges By Investing.com - Investing.com South Africa
RBC Capital Sticks to Its Buy Rating for Agios Pharma (AGIO) - The Globe and Mail
Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says - MarketScreener
New Strong Sell Stocks for April 3rd - TradingView
Agios stock touches 52-week low at $27.12 amid market shifts - Investing.com India
Agios stock touches 52-week low at $27.12 amid market shifts By Investing.com - Investing.com South Africa
Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
10 Best Small-Cap Stocks to Buy Before They Explode - Insider Monkey
First Week of November 21st Options Trading For Agios Pharmaceuticals (AGIO) - Nasdaq
Agios Pharmaceuticals divulges new PAH stabilizers for phenylketonuria - BioWorld MedTech
Beta Thalassemia Market Predicted to See Upsurge Through 2034, - openPR
Agios Pharmaceuticals at Barclays Conference: Strategic Advances in Rare Disease Treatments - Investing.com UK
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):